Activity Overview
There are numerous pharmacologic options for treatment of chronic pain. Some clinicians are hesitant to prescribe these medications
due to concerns about drug addiction and adverse events such as respiratory depression.
Unfortunately, some pain has no cure. It may be nociceptive, neuropathic, or disease specific. Left untreated, chronic pain may
affect sleep, quality of life, mental health, and productivity. The condition is difficult to diagnose and manage because an individual's perception of his or her pain is subjective, and the cause varies between patients. Community pharmacists are readily available to patients and colleagues for questions regarding pain management. They can assess patients' risk for abuse and optimize
treatment strategies for improved patient outcomes. In addition, they provide physicians and staff with important information
regarding administration, side effects, drug interaction potential, and efficacy of pharmacologic agents used to address chronic
pain. In order to provide this type of care, community pharmacists need an in-depth understanding of all the available and emerging
technologies and options for long-acting pain management.This activity will focus on the current state of chronic pain management,
various advances in treatment options, and how these issues speak to the pharmacist working in the community setting.
Agenda
| 10 minutes |
Introduction and Pre-Webcast Outcomes Survey Bruce R. Canaday, PharmD, FAPhA, FASHP |
| 35 minutes |
Current State of Chronic Pain Management:
Current and Emerging Long-Acting Opioids
Lynn Webster, MD, FACPM, FASAM |
| 35 minutes |
Perspectives for the Community Pharmacist
Sheldon J. Rich, RPh, PhD |
| 10 minutes |
Faculty Debate and Post-Webcast Outcomes Survey
Bruce R. Canaday, PharmD, FAPhA, FASHP |
Goal
This activity has been designed to enhance the community pharmacist's understanding of the existing and emerging pharmacologic treatments for
chronic pain; to provide strategies for improving pain control, risk management, and quality of life; and to identify and manage barriers associated with long-acting
opioid therapy in order to provide optimal patient outcomes.
Intended Audience
This activity is designed for community pharmacists. No prerequisites required.
Learning Objectives
The University of Tennessee College of Pharmacy takes responsibility for
the content, quality, and scientific integrity of this CPE activity.
Upon the conclusion of this activity, the participant should be able to:
- REVIEW existing and emerging pharmacologic treatment options for
chronic pain.
- IDENTIFY barriers associated with opioid therapy and methods to
overcome these obstacles to optimize treatment.
- DIFFERENTIATE between new and emerging treatment options relating
to emerging opioid therapies.
- MANAGE symptom control and improve quality of life in patients with
chronic pain.
- REVIEW and DISCUSS retail pharmacy implications of the Risk Evaluation
and Mitigation Strategies (REMS) program.
Accreditation Statement
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing
education for pharmacists.
Credit Designation Statement
This knowledge-based activity is sponsored by The University of Tennessee College of Pharmacy who is accredited by the
Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.Successful completion of this knowledge-based educational
activity will provide 1.5 contact hours credit (0.15 CEUs). A statement of CPE credit will be available online immediately following successful
completion of the activity. Successful completion includes attending the on-line session, completing the pre- and post-test, and completing the
educational activity evaluation. For April 27 live webcast: ACPE Program #064-000-10-202-L01-P; for May 13, May 18, June 2, and June 8 home study
webcasts: ACPE Program #064-000-10-202-H01-P.
Faculty
Bruce R. Canaday, PharmD,
FAPhA, FASHP (Chair)
Clinical Professor and Vice-Chair Division of Pharmacy Practice and Experiential Education
University of North Carolina Eshelman
School of Pharmacy
Chapel Hill, North Carolina
Lynn Webster, MD, FACPM, FASAM
Utah Academy of Pain Medicine
Lifetree Clinical Research and Pain Clinic
Salt Lake City, Utah
Sheldon J. Rich, RPh, PhD
President–SJR Associates, LLC
Adjunct Clinical Assistant Professor–University of Michigan
Adjunct Assistant Professor–Wayne State University
Palm Beach Gardens, Florida
Policy on Faculty and Provider Disclosure
It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real
or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices
during the presentation(s). Detailed disclosures will be made in the online materials.
Americans with Disabilities Act (ADA)
The University of Tennessee College of Pharmacy fully complies with the legal requirements of the ADA and the rules
and regulations thereof. Please notify us if you have any special needs.
Grievance Policy
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an educational activity
sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing. The grievance
will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of
Pharmacy can be made for a second level review.
Fee Information
There is no fee for this educational activity. |